Sequana Medical NV (SEQUA) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.254x

Based on the latest financial reports, Sequana Medical NV (SEQUA) has a cash flow conversion efficiency ratio of 0.254x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.93 Million ≈ $-11.61 Million USD) by net assets (€-39.17 Million ≈ $-45.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Sequana Medical NV - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Sequana Medical NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Sequana Medical NV carry for a breakdown of total debt and financial obligations.

Sequana Medical NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sequana Medical NV ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Zim Laboratories Limited
NSE:ZIMLAB
0.031x
Magnitude International Ltd Ordinary Shares
NASDAQ:MAGH
N/A
Molinos Juan Semino SA
BA:SEMI
0.001x
Tolins Tyres Ltd
NSE:TOLINS
N/A
Yuasa Battery (Thailand) Public Company Limited
BK:YUASA
0.099x
Davolink Inc.
KQ:340360
0.488x
2S Metal Public Company Limited
BK:2S
0.007x
Panagene Inc
KQ:046210
0.001x

Annual Cash Flow Conversion Efficiency for Sequana Medical NV (2015–2024)

The table below shows the annual cash flow conversion efficiency of Sequana Medical NV from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Sequana Medical NV worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €-44.38 Million
≈ $-51.88 Million
€-20.26 Million
≈ $-23.68 Million
0.456x -69.43%
2023-12-31 €-19.47 Million
≈ $-22.76 Million
€-29.06 Million
≈ $-33.98 Million
1.493x -88.30%
2022-12-31 €-2.15 Million
≈ $-2.52 Million
€-27.48 Million
≈ $-32.13 Million
12.763x -57.47%
2021-12-31 €-786.92K
≈ $-919.99K
€-23.62 Million
≈ $-27.61 Million
30.012x +119.90%
2020-12-31 €112.76K
≈ $131.83K
€-17.01 Million
≈ $-19.88 Million
-150.806x -655.51%
2019-12-31 €925.93K
≈ $1.08 Million
€-18.48 Million
≈ $-21.61 Million
-19.961x -3891.86%
2018-12-31 €-18.76 Million
≈ $-21.93 Million
€-9.88 Million
≈ $-11.55 Million
0.526x -72.08%
2017-12-31 €-4.61 Million
≈ $-5.39 Million
€-8.69 Million
≈ $-10.16 Million
1.885x -1.40%
2016-12-31 €-6.67 Million
≈ $-7.80 Million
€-12.75 Million
≈ $-14.90 Million
1.912x -95.17%
2015-12-31 €-284.66K
≈ $-332.79K
€-11.26 Million
≈ $-13.16 Million
39.554x --

About Sequana Medical NV

BR:SEQUA Belgium Medical Devices
Market Cap
$46.97 Million
€40.18 Million EUR
Market Cap Rank
#22168 Global
#94 in Belgium
Share Price
€0.61
Change (1 day)
+0.00%
52-Week Range
€0.47 - €1.54
All Time High
€11.80
About

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more